• On April 23, GlaxoSmithKline announced an offer worth $720 million to acquire drug developer Sirtris Pharmaceuticals. Sirtris's research focuses on developing anti-aging compounds, such as the chemical resveratrol found in red wine which may lower blood sugar in diabetics and extend lifespan. This offer represents a substantial investment from GSK on early-stage research of potentially very profitable drugs. GSK shares rose by 2 percent to $44.61.
The FDA did not approve 500/50 strength Advair Diskus, a new dosage of the treatment for chronic obstructive pulmonary disease (COPD).
An FDA Committee recommended that despite possible links between Avandia, a diabetes medication, and heart failure, it should remain on the market.
The FDA issued an alert on the safety of major diabetes drug Avandia, claiming that it might be causing heart failure.
Edit Metric
